Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140403 | 1.00 | L3MBTL1 (0.35) | L3MBTL1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2141481 | 0.89 | AXL (0.33) | L3MBTL1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1978407 | 0.87 | GRIN1 (0.34) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL1973109 | 0.87 | GRIN1 (0.36) | — | |
| SCHEMBL1978405 | 0.87 | GRIN1 (0.34) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL1973110 | 0.87 | GRIN1 (0.36) | — | |
| SCHEMBL5410717 | 0.87 | ALDH1A1 (0.37) | L3MBTL1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2142968 | 0.87 | ALDH1A1 (0.37) | L3MBTL1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1975331 | 0.86 | KDM4E (0.35) | L3MBTL1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3194634 | 0.86 | KDM4E (0.32) | KDM4EALDH1A1HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148407-B2 | Compounds derived from 5-thioxylose and their use in therapeutics | LABORATORIES FOURNIER S.A. (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | INVENTIVA (FR) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | TPMT, STS, TBXAS1 | L3MBTL1 1133/4885KDM4E 1733/4885ALDH1A1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.